Finance

A collection of 311 posts

Markets Featured

Washington Approved Hollywood's Biggest Merger. Twelve States Said No.

The $111 billion Paramount-Warner Bros. merger cleared the DOJ, the EU, and shareholders — then 12 state attorneys general froze it until 2027. Inside the fight over who actually polices American mergers, and what Wall Street's 85% bet misses.

Paid-members only

Markets Featured

Merck's Answer to Pharma's Biggest Patent Cliff Costs $10.50 a Day

The first cholesterol pill in the PCSK9 class just reached US pharmacies at $315 a month — a tenth of what its injectable predecessors launched at. Inside the launch that has to fill the Keytruda hole, the revenue scenarios, and the three tickers on the wrong side of it.

Finance Featured

The Biggest New Buyer of American Debt Isn't a Country

Stablecoin issuers now hold more US Treasuries than Germany — a buyer Washington legislated into existence. The fiscal math behind it, and the risk nobody has stress-tested at scale.

Markets Featured

There Are Only 32 of Them, and They're Not Making Any More

The NFL just repriced itself by 31% in a single year. A record $9.6 billion Seahawks sale, private equity's arrival, and fixed supply meeting a growing billionaire class — inside the trophy-asset boom reshaping American sports.

Paid-members only

Markets Featured

$RARE: Ultragenyx Lost Its Biggest Program Overnight. The Next FDA Decision Is 16 Days Away.

A clean Phase 3 miss in Angelman syndrome deleted $1.2 billion from Ultragenyx overnight, leaving a growing $745M revenue base priced below 2x sales sixteen days before its next FDA decision. Scenario zones inside.

Macro Featured

The American Consumer Is Fine. Millions of Americans Are Not.

Credit card delinquencies look like 2008 — until the NY Fed shows why the chart is misleading. What the data really says about America's bifurcating consumer economy, and how to position for it.

Paid-members only

Macro Featured

The World's Biggest Creditor Is Coming Home

Japan's 10-year yield just hit 3% for the first time since 1996 — and the largest foreign holder of US Treasuries has started bringing $1.2 trillion home. The transmission map for your portfolio, before the September 17 BOJ meeting.

Paid-members only

Finance Featured

$RZLV: Revenue Grew 1,970%. The Stock Fell 20% Anyway.

Rezolve AI beat its own pre-announcement and reaffirmed $360M for the year — and the market sold it toward a 52-week low anyway. The margin mix, the cash math, and the revised scenario zones into October 6.

Paid-members only

Markets Featured

Your Emerging Markets Fund Is an AI Fund Now

EM currencies at record highs, record inflows, best start since 2017 — in the middle of an oil war and a hawkish Fed. The rally is real; the label isn't. Three chip stocks now outweigh the actual emerging markets inside the index — and both halves of that split are mispriced.

Paid-members only

Markets Featured

$RZLV: Rezolve AI Is About to Report H1. The Math Behind Its $360 Million Year Starts Tomorrow.

Rezolve AI has reported preliminary H1 2026 revenue of $127 million -- nearly 20 times year-over-year growth. Tomorrow it reports officially and hosts an investor call. The question the market is lining up to answer: can H2 deliver the $233 million still needed to hit full-year guidance?

Paid-members only

Macro Featured

Who Took the Other Side of Japan's Record Yen Defense?

Japan just spent $96.5 billion in a month defending the yen — the largest intervention in its history, the first joint operation with the US since 1998 — and the dollar is back at ¥160. The flow data reveals who took the other side, and why September's BOJ meeting is now the whole game.

Markets Featured

The New Master Settlement

Meta just paid $16.7 billion to end the state AGs' child-safety case — and its stock went up. Inside the settlement structure that capped a trillion-dollar liability, and the clause that sent the bill to YouTube, TikTok, and Snap.

Paid-members only

Finance Featured

Why Would Gilead Compete With Its Own Best-Selling Drug?

The FDA just approved Bixlenvo — a Gilead pill aimed at a sliver of the HIV market and, quietly, at the company's own $13.4 billion best-seller. Inside the franchise migration that decides what Gilead is worth after 2036.

Finance Featured

What Happens When a Salary Cap Has No Union?

College football opens its 2026 season with $23 million median payrolls, a $21.3 million salary cap, and general managers — everything a pro league has except a deal with labor. That gap is the sport's next financial fault line.

Paid-members only

Finance Featured

Crypto Is Buying Out Its Own VCs

Ethena just bought out its seed investors and pledged 95% of revenue to buybacks. Hyperliquid walks into a $1.2 billion unlock at an all-time high tomorrow. The VC-unlock era of tokenomics is ending — here is the framework for pricing what replaces it.

Paid-members only

Markets Featured

$MRVL: Marvell Reported a Perfect Quarter. The Stock Fell Anyway. Here Is What the Market Is Actually Saying.

test

Paid-members only

Finance Featured

The Basis Trade Nearly Broke the Treasury Market Twice. Now Washington Is Bringing It Inside.

Four months before the SEC's clearing mandate hits the world's most important market, Washington's answer to the $1 trillion basis trade isn't to shrink it — it's to move it inside the clearinghouse. Who collects the new tolls, and what can still break by December 31.

Markets Featured

$DLTR: Dollar Tree Beat Q2 Earnings. The $252 Million Tariff Refund It Won't Get Again Is Why the Stock Is Falling.

Dollar Tree posted a Q2 EPS that nearly tripled analyst estimates — but strip out $1.31 of one-time tariff refunds, and the underlying picture looks different. With Q3 guidance 37% below consensus, the question isn't whether Dollar Tree beat the quarter. It's whether the consumer actually showed up.

Markets Featured

How Much Is Doubling Pancreatic Cancer Survival Worth?

The FDA just approved daraxonrasib, the first drug to double survival in pancreatic cancer — and the first to crack the 'undruggable' RAS protein after forty years. Inside the science, the $46 billion company that refused to sell, and the race the approval just started.

Paid-members only

Finance Featured

$BBWI: Bath & Body Works Reported a Beat. The $80 Million Tariff Refund It Won't Get Again Is Why the Stock Is Down.

Bath & Body Works beat Q2 consensus by 2.4x while the stock fell 8%. The discrepancy lives in a non-recurring $80M tariff refund — and a Q3 guide showing EPS declining 75% year-over-year. Here's the math behind the move, the balance sheet, and the scenario zones.

Macro Featured

What Happens to a Town When Its College Dies?

The enrollment cliff arrived on campus this month — not as a uniform decline, but as a sorting. Flagships are posting record classes while small colleges close, and the losses are landing on towns built on the assumption the campus is permanent.

Paid-members only

Markets Featured

$DKS: Dick's Sporting Goods Paid $2.4 Billion for Foot Locker. Today's Earnings Reveal What That Bet Is Worth.

Dick's Q2 split the company in two: the DICK'S Business delivered 4.9% comp growth on World Cup momentum; Foot Locker slipped 3.6%. DKS is gapping down 15% to a new 52-week low. The real question is whether the footwear market softness is a temporary trough or something structural.

Paid-members only

Markets Featured

The Alzheimer's Bottleneck Was Never the Drugs

The FDA just cleared the first blood test that can both confirm and rule out Alzheimer's pathology from a routine blood draw — in primary care, on analyzers already installed in 4,500 US labs. The $26,500-a-year drugs were never the constraint. The diagnosis was.

Paid-members only

Markets Featured

$AAOI: An FCC Ban on Chinese Optics Just Created a 60% Market Gap. Can Applied Optoelectronics Fill It?

Applied Optoelectronics just posted its fifth straight record quarter on 86% revenue growth while the FCC drafts a ban that could restructure who builds the backbone of AI infrastructure. The numbers behind the setup are more complex than the headlines suggest.

Markets Featured

How Las Vegas Replaced the Tourists Who Stopped Coming

Las Vegas visitation looks stable again — but the tourists holding the line aren't the ones who left. Inside the customer swap that reprices the Strip, and what it reveals about the American consumer.